文献速递临床试验与 GCP

低强度全身振动联合或不联合高强度抗阻与冲击训练对低骨量绝经后女性股骨近端脆性骨折危险因素的影响:VIBMOR随机对照试验研究方案

The effect of low-intensity whole-body vibration with or without high-intensity resistance and impact training on risk factors for proximal femur fragility fracture in postmenopausal women with low bone mass: study protocol for the VIBMOR randomized controlled trial.
PubMed 文献 · Trials · 2022-01-06

VIBMOR试验将低骨量绝经后女性随机分为低强度全身振动(LIV)、骨靶向高强度抗阻与冲击训练(HiRIT)、LIV+HiRIT或对照组,干预9个月,主要结局为双能X线吸收法测定的全髋面积骨密度(aBMD),并在干预后及1年后随访评估去训练效应。

要点

  • 比较LIV、HiRIT及两者联合对绝经后低骨量女性髋部骨折危险因素的疗效。
  • 主要结局为双能X线吸收法测定的全髋面积骨密度(aBMD)。
  • 干预9个月,并在21个月时评估去训练效应。

核心结论

  • 尚无研究比较LIV单用或联合骨靶向HiRIT(联合或不联合骨质疏松药物)对低骨量绝经后女性髋部骨折危险因素的影响。
  • 若任一、两者或联合机械干预安全有效,将为对骨质疏松药物无反应、不愿或不能服药的脆性骨折高风险个体提供替代治疗途径。

研究设计与样本

  • VIBMOR为随机对照试验,招募股骨近端和/或腰椎面积骨密度(aBMD)低的绝经后女性,伴或不伴脆性骨折史,正在或未用骨质疏松药物。
  • 合格参与者随机分配至四个试验组之一,为期9个月:LIV、HiRIT、LIV+HiRIT或对照(低强度家庭运动)。
  • 分配采用区组随机,按骨质疏松药物使用分层。
  • 测试时间点:基线(T0)、干预后(T1;9个月)及此后1年(T2;21个月)以评估去训练效应。

关键数值与推荐

  • 主要结局为双能X线吸收法(DXA)测定的全髋aBMD。
  • 次要结局包括其他部位aBMD、人体测量学及其他骨强度指标、身体成分、躯体功能、驼背、肌力与爆发力、平衡、跌倒及干预依从性。
  • 探索性结局包括骨转换标志物、盆底健康、生活质量、体育活动愉悦感、不良事件及骨折。
  • 将进行经济学评价。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevailing medical opinion is that medication is the primary (some might argue, only) effective intervention for osteoporosis. It is nevertheless recognized that osteoporosis medications are not universally effective, tolerated, or acceptable to patients. Mechanical loading, such as vibration and exercise, can also be osteogenic but the degree, relative efficacy, and combined effect is unknown. The purpose of the VIBMOR trial is to determine the efficacy of low-intensity whole-body vibration (LIV), bone-targeted, high-intensity resistance and impact training (HiRIT), or the combination of LIV and HiRIT on risk factors for hip fracture in postmenopausal women with osteopenia and osteoporosis. METHODS: Postmenopausal women with low areal bone mineral density (aBMD) at the proximal femur and/or lumbar spine, with or without a history of fragility fracture, and either on or off osteoporosis medications will be recruited. Eligible participants will be randomly allocated to one of four trial arms for 9 months: LIV, HiRIT, LIV + HiRIT, or control (low-intensity, home-based exercise). Allocation will be block-randomized, stratified by use of osteoporosis medications. Testing will be performed at three time points: baseline (T0), post-intervention (T1; 9 months), and 1 year thereafter (T2; 21 months) to examine detraining effects. The primary outcome measure will be total hip aBMD determined by dual-energy X-ray absorptiometry (DXA). Secondary outcomes will include aBMD at other regions, anthropometrics, and other indices of bone strength, body composition, physical function, kyphosis, muscle strength and power, balance, falls, and intervention compliance. Exploratory outcomes include bone turnover markers, pelvic floor health, quality of life, physical activity enjoyment, adverse events, and fracture. An economic evaluation will also be conducted. DISCUSSION: No previous studies have compared the effect of LIV alone or in combination with bone-targeted HiRIT (with or without osteoporosis medications) on risk factors for hip fracture in postmenopausal women with low bone mass. Should either, both, or combined mechanical interventions be safe and efficacious, alternative therapeutic avenues will be available to individuals at elevated risk of fragility fracture who are unresponsive to or unwilling or unable to take osteoporosis medications. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (www. anzctr.org.au ) (Trial number ANZCTR12615000848505, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id = 368962 ); date of registration 14/08/2015 (prospectively registered). Universal Trial Number: U1111-1172-3652.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Beck B, Rubin C, Harding A, et al. The effect of low-intensity whole-body vibration with or without high-intensity resistance and impact training on risk factors for proximal femur fragility fracture in postmenopausal women with low bone mass: study protocol for the VIBMOR randomized controlled trial. Trials. 2022. PMID: 34991684. doi:10.1186/s13063-021-05911-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。